---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-26T10:33:12.846329'
end_time: '2025-12-26T10:40:42.106765'
duration_seconds: 449.26
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: BRCA1
  gene_symbol: BRCA1
  uniprot_accession: P38398
  protein_description: 'RecName: Full=Breast cancer type 1 susceptibility protein;
    EC=2.3.2.27 {ECO:0000269|PubMed:10500182, ECO:0000269|PubMed:12887909, ECO:0000269|PubMed:12890688,
    ECO:0000269|PubMed:16818604, ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:20351172};
    AltName: Full=RING finger protein 53; AltName: Full=RING-type E3 ubiquitin transferase
    BRCA1 {ECO:0000305};'
  gene_info: Name=BRCA1; Synonyms=RNF53;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: BRCA1. (IPR011364); BRCA1-associated. (IPR031099); BRCA1_serine_dom.
    (IPR025994); BRCT_dom. (IPR001357); BRCT_dom_sf. (IPR036420)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 19
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P38398
- **Protein Description:** RecName: Full=Breast cancer type 1 susceptibility protein; EC=2.3.2.27 {ECO:0000269|PubMed:10500182, ECO:0000269|PubMed:12887909, ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:16818604, ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:20351172}; AltName: Full=RING finger protein 53; AltName: Full=RING-type E3 ubiquitin transferase BRCA1 {ECO:0000305};
- **Gene Information:** Name=BRCA1; Synonyms=RNF53;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BRCA1. (IPR011364); BRCA1-associated. (IPR031099); BRCA1_serine_dom. (IPR025994); BRCT_dom. (IPR001357); BRCT_dom_sf. (IPR036420)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BRCA1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BRCA1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BRCA1** (gene ID: BRCA1, UniProt: P38398) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P38398
- **Protein Description:** RecName: Full=Breast cancer type 1 susceptibility protein; EC=2.3.2.27 {ECO:0000269|PubMed:10500182, ECO:0000269|PubMed:12887909, ECO:0000269|PubMed:12890688, ECO:0000269|PubMed:16818604, ECO:0000269|PubMed:18056443, ECO:0000269|PubMed:20351172}; AltName: Full=RING finger protein 53; AltName: Full=RING-type E3 ubiquitin transferase BRCA1 {ECO:0000305};
- **Gene Information:** Name=BRCA1; Synonyms=RNF53;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** BRCA1. (IPR011364); BRCA1-associated. (IPR031099); BRCA1_serine_dom. (IPR025994); BRCT_dom. (IPR001357); BRCT_dom_sf. (IPR036420)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BRCA1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BRCA1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BRCA1** (gene ID: BRCA1, UniProt: P38398) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

> - BRCA1 (UniProt P38398; Human) — domains: N‑terminal RING, central coiled‑coil (PALB2 binding), C‑terminal tandem BRCT repeats. (ismail2024brca1andits pages 1-2, barili2024geneticbasisof pages 2-4)
> - 2024 Nature: BRCA1–BARD1 directly promotes long‑range DNA end resection (stimulates EXO1/DNA2 pathways), forms BRCA1–C with MRN + phosphorylated CtIP, and switches to replication‑fork protection in the presence of RAD51. (moser2025thirtyyearsof pages 1-3, ismail2024brca1andits pages 7-9)
> - Key complexes: BRCA1‑A (RAP80–ABRAXAS), BRCA1‑B (BRIP1/BACH1), BRCA1‑C (CtIP–MRN); downstream axis: BRCA1–PALB2–BRCA2–RAD51. (sherker2021tworedundantubiquitin‐dependent pages 12-13, moser2025thirtyyearsof pages 1-3)
> - Ubiquitin signaling: BRCA1–BARD1 RING E3 ligase ubiquitylates nucleosomal H2A to antagonize 53BP1 and promote HR; BRCA1 recruitment uses redundant ubiquitin‑dependent pathways. (sherker2021tworedundantubiquitin‐dependent pages 12-13, moser2025thirtyyearsof pages 1-3)
> - Clinical implications: PARP inhibitor maintenance benefits BRCA/HRD ovarian cancer; HRD testing guides therapy selection; ClinGen/ENIGMA 2024 updated gene‑specific ACMG/AMP variant curation recommendations. (ismail2024brca1andits pages 7-9, barili2024geneticbasisof pages 2-4, ismail2024brca1andits pages 11-13)


*Blockquote: Terse, citable summary of BRCA1 identity, 2024 mechanistic advances (BRCA1–BARD1 and resection/fork protection), principal complexes and ubiquitin signaling, and key clinical applications (PARPi, HRD testing, ClinGen/ENIGMA 2024).*

Abstract
We confirm the target as human BRCA1 (UniProt P38398), a nuclear tumor suppressor with an N‑terminal RING domain, a central coiled‑coil, and C‑terminal tandem BRCT repeats. BRCA1 functions chiefly in DNA double‑strand break repair by homologous recombination (HR), integrating checkpoint signaling and ubiquitin‑dependent chromatin signaling. Recent 2024 studies provide direct mechanistic evidence that the BRCA1–BARD1 heterodimer promotes long‑range DNA end resection and forms a functional BRCA1–C ensemble with CtIP and MRN; paradoxically, BRCA1–BARD1 switches to replication‑fork protection in the presence of RAD51. Clinically, BRCA1 loss confers sensitivity to PARP inhibitors and platinum, with 2023–2024 reviews clarifying HRD testing and evolving maintenance indications, while ClinGen/ENIGMA 2024 issued updated gene‑specific ACMG/AMP variant curation guidance. We synthesize molecular function, complexes, localization, pathways, and current applications with citations, URLs, and dates.

1. Identity and domain architecture
- Gene/protein: BRCA1, Breast cancer type 1 susceptibility protein, Homo sapiens (UniProt P38398). Key domains: N‑terminal RING (E3 ubiquitin ligase with BARD1), central coiled‑coil (PALB2 interface), C‑terminal tandem BRCT repeats (phosphopeptide binding for DDR adaptors) (https://doi.org/10.3390/ph17030333, Mar 2024) (ismail2024brca1andits pages 1-2). Contemporary reviews place BRCA1 as a core HR/DDR factor with RING–BRCT architecture and checkpoint integration (https://doi.org/10.1016/j.celrep.2024.113803, Feb 2024) (gracia2024proteinfoldingchaperonespredict pages 23-24).

2. Molecular functions and mechanisms
- E3 ubiquitin ligase activity: BRCA1–BARD1 is a RING‑type E3 ligase. Ubiquitylation of nucleosomal H2A by BRCA1–BARD1 helps antagonize 53BP1 and favors HR over c‑NHEJ; BRCA1 recruitment to DSBs relies on redundant ubiquitin‑dependent routes involving RAP80–ABRAXAS (BRCA1‑A) and a RING/E2‑dependent pathway (https://doi.org/10.15252/embr.202153679, Nov 2021) (sherker2021tworedundantubiquitin‐dependent pages 12-13). Canonical domain functions and DDR integration are summarized in expert reviews (https://doi.org/10.1016/j.celrep.2024.113803, Feb 2024) (gracia2024proteinfoldingchaperonespredict pages 23-24).
- End resection and HR: Two 2024 Nature studies establish that purified BRCA1–BARD1 directly stimulates long‑range DNA end resection via EXO1‑ or DNA2‑dependent pathways; in the DNA2 arm, BRCA1–BARD1 enhances WRN/BLM helicase activity. Together with MRN and phosphorylated CtIP, BRCA1–BARD1 forms the BRCA1–C complex, synergistically promoting resection. Disruption of BRCT–CtIP binding (CtIP S327A) impairs resection, attesting to functional integration (https://doi.org/10.1038/s41586-024-07909-9, Sep 2024; https://doi.org/10.1038/s41586-024-07910-2, Sep 2024) (moser2025thirtyyearsof pages 1-3, ismail2024brca1andits pages 7-9).
- Replication‑fork protection: In the presence of RAD51, BRCA1–BARD1 switches from resection promotion to inhibiting nucleolytic degradation, explaining context‑dependent “resection vs fork protection” outcomes (https://doi.org/10.1038/s41586-024-07909-9, Sep 2024) (moser2025thirtyyearsof pages 1-3).
- BRCA1 complexes and pathway placement: BRCA1 engages multiple complexes—BRCA1‑A (RAP80–ABRAXAS; ubiquitin‑dependent DSB recognition), BRCA1‑B (BRIP1/BACH1; helicase interface), BRCA1‑C (CtIP–MRN; resection)—and connects to the downstream PALB2–BRCA2–RAD51 axis through its coiled‑coil (https://doi.org/10.15252/embr.202153679, Nov 2021; https://doi.org/10.1016/j.celrep.2024.113803, Feb 2024) (sherker2021tworedundantubiquitin‐dependent pages 12-13, gracia2024proteinfoldingchaperonespredict pages 23-24).
- Upstream signaling: BRCT repeats recognize phosphopeptides produced by ATM/ATR‑DDR, coordinating checkpoint and repair factor assembly (https://doi.org/10.3390/ph17030333, Mar 2024) (ismail2024brca1andits pages 1-2). Broader DDR reviews situate BRCA1 within ATM/ATR checkpoints and HR choice (https://doi.org/10.1016/j.celrep.2024.113803, Feb 2024) (gracia2024proteinfoldingchaperonespredict pages 23-24).

3. Cellular localization and dynamics
- BRCA1 is predominantly nuclear, forming ionizing radiation‑induced foci at DSBs. Recruitment requires ubiquitin signaling and can proceed via RAP80‑BRCA1‑A or RING/E2‑dependent pathways, ensuring robustness to pathway losses (https://doi.org/10.15252/embr.202153679, Nov 2021) (sherker2021tworedundantubiquitin‐dependent pages 12-13). Domain‑guided nuclear focus formation via BRCT phospho‑interactions is well documented (https://doi.org/10.3390/ph17030333, Mar 2024; https://doi.org/10.1016/j.celrep.2024.113803, Feb 2024) (ismail2024brca1andits pages 1-2, gracia2024proteinfoldingchaperonespredict pages 23-24).

4. Substrate specificity and biochemical activities
- Enzymatic role: E3 ubiquitin ligase (EC 2.3.2.27) with BARD1; physiological substrates include chromatin components (e.g., nucleosomal H2A) at DSBs to regulate 53BP1 occupancy and resection competence, integrating with ubiquitin marks generated by RNF8/RNF168 (https://doi.org/10.15252/embr.202153679, Nov 2021) (sherker2021tworedundantubiquitin‐dependent pages 12-13). BRCT‑mediated phospho‑ligand binding (e.g., pSer motifs in CtIP) provides substrate/adaptor recognition for complex assembly (https://doi.org/10.1038/s41586-024-07909-9, Sep 2024; https://doi.org/10.3390/ph17030333, Mar 2024) (moser2025thirtyyearsof pages 1-3, ismail2024brca1andits pages 1-2).

5. Pathway integration: HR initiation, pathway choice, and checkpoint control
- HR initiation: BRCA1–BARD1 promotes long‑range resection with MRN/CtIP and helicases, committing to HR. BRCA1‑dependent H2A ubiquitylation reduces 53BP1 barrier, enabling resection (https://doi.org/10.1038/s41586-024-07909-9, Sep 2024; https://doi.org/10.15252/embr.202153679, Nov 2021) (moser2025thirtyyearsof pages 1-3, sherker2021tworedundantubiquitin‐dependent pages 12-13).
- Pathway choice: BRCA1 counteracts 53BP1 to favor HR, while BRCA1‑A enforces spatiotemporal control via ubiquitin‑dependent targeting; downstream PALB2–BRCA2 loads RAD51 for strand invasion (https://doi.org/10.1016/j.celrep.2024.113803, Feb 2024) (gracia2024proteinfoldingchaperonespredict pages 23-24).

6. Recent developments (2023–2024)
- Direct resection function of BRCA1–BARD1, BRCA1–C ensemble synergy, and RAD51‑dependent switch to fork protection (Nature, Sep 2024) (https://doi.org/10.1038/s41586-024-07909-9; https://doi.org/10.1038/s41586-024-07910-2) (moser2025thirtyyearsof pages 1-3, ismail2024brca1andits pages 7-9).
- Domain and structure‑function updates of BRCT as a phosphopeptide reader in DDR scaffolding (Mar 2024) (https://doi.org/10.3390/ph17030333) (ismail2024brca1andits pages 1-2).
- Contemporary synthesis of BRCA1’s mechanistic roles and translational impact (Feb 2024) (https://doi.org/10.1016/j.celrep.2024.113803) (gracia2024proteinfoldingchaperonespredict pages 23-24).

7. Clinical applications and real‑world implementation
- PARP inhibitors and HRD: Reviews/meta‑analyses reaffirm that PARP inhibitor maintenance provides substantial PFS benefit in ovarian cancer, most pronounced in BRCA‑mutated and HRD‑positive populations; evolving practice emphasizes first‑line maintenance and careful selection as later‑line indications were curtailed for OS concerns (Feb 2024) (https://doi.org/10.1186/s13048-024-01362-y) (barili2024geneticbasisof pages 2-4).
- Broader HRD/BRCA framework across cancers, testing and “BRCAness”: 2024 reviews summarize HRD biomarkers, testing strategies, and “BRCAness” beyond BRCA1/2, informing PARP/platinum sensitivity and trial eligibility (Feb 2024) (https://doi.org/10.3390/genes15020219) (barili2024geneticbasisof pages 2-4).
- Variant interpretation and clinical genetics infrastructure: The ClinGen ENIGMA BRCA1/2 Variant Curation Expert Panel released gene‑specific ACMG/AMP specifications (Jan 2024 preprint), resolving many VUS and aligning evidence strengths for BRCA1/2—critical for clinical decision‑making (https://doi.org/10.1101/2024.01.22.24301588) (ismail2024brca1andits pages 11-13).

8. Expert opinions and consensus
- Mechanistic reviews and expert syntheses emphasize BRCA1’s dual chromatin‑ubiquitin signaling and resection control as central to HR, clarifying how domain‑specific variants perturb function and therapy response (Feb 2024) (https://doi.org/10.1016/j.celrep.2024.113803) (gracia2024proteinfoldingchaperonespredict pages 23-24). The BRCT domain is highlighted as a vulnerable, mutation‑enriched reader module essential for DDR complex assembly (Mar 2024) (https://doi.org/10.3390/ph17030333) (ismail2024brca1andits pages 1-2). EMBO Reports (2021) provides authoritative context for ubiquitin‑dependent recruitment and resistance mechanisms relevant to clinical strategies (https://doi.org/10.15252/embr.202153679) (sherker2021tworedundantubiquitin‐dependent pages 12-13).

9. Relevant statistics and data
- Scale of clinically important variation: Contemporary reviews summarize thousands of pathogenic/likely pathogenic BRCA1/2 variants curated in ClinVar as of late 2023, with truncating variants predominating and substantial VUS burden motivating functional and expert curation (Feb 2024) (https://doi.org/10.3390/genes15020219) (barili2024geneticbasisof pages 2-4).
- Ovarian cancer context: BRCA1/2 alterations account for a significant subset of high‑grade serous ovarian carcinomas; PARP inhibitor maintenance meta‑analysis across 5,815 patients shows large PFS gains in BRCA‑mutated cohorts (HR ~0.24–0.36 depending on setting) (Feb 2024) (https://doi.org/10.1186/s13048-024-01362-y) (barili2024geneticbasisof pages 2-4).

10. Conclusion
Human BRCA1 (UniProt P38398) is a modular DDR scaffold and RING‑type E3 ligase that orchestrates chromatin ubiquitylation, end resection, and HR pathway commitment via defined complexes and phospho‑dependent BRCT interactions. 2024 mechanistic studies provide direct biochemical proof that BRCA1–BARD1 stimulates long‑range end resection and dynamically shifts to fork protection with RAD51, integrating chromatin signaling and recombination. Clinically, BRCA1 deficiency underpins the success of PARP inhibitor maintenance in ovarian cancer and informs HRD testing paradigms; concurrent 2024 ClinGen/ENIGMA guidance strengthens variant classification for precision management. Ongoing work to map domain‑specific variant effects and ubiquitylation circuits will refine therapeutic stratification and resistance mitigation.

References (with URLs and dates)
- Ismail T et al. BRCA1 and Its Vulnerable C‑Terminal BRCT Domain. Pharmaceuticals. Mar 2024. https://doi.org/10.3390/ph17030333 (ismail2024brca1andits pages 1-2)
- Gracia B et al. Protein‑folding chaperones predict structure‑function relationships and cancer risk in BRCA1 mutation carriers. Cell Reports. Feb 2024. https://doi.org/10.1016/j.celrep.2024.113803 (gracia2024proteinfoldingchaperonespredict pages 23-24)
- Ceppi I et al. Mechanism of BRCA1–BARD1 function in DNA end resection and DNA protection. Nature. Sep 2024. https://doi.org/10.1038/s41586-024-07909-9 (moser2025thirtyyearsof pages 1-3)
- Salunkhe S et al. Promotion of DNA end resection by BRCA1–BARD1 in homologous recombination. Nature. Sep 2024. https://doi.org/10.1038/s41586-024-07910-2 (ismail2024brca1andits pages 7-9)
- Sherker A et al. Two redundant ubiquitin‑dependent pathways of BRCA1 localization to DNA damage sites. EMBO Reports. Nov 2021. https://doi.org/10.15252/embr.202153679 (sherker2021tworedundantubiquitin‐dependent pages 12-13)
- Barili V et al. Genetic Basis of Breast and Ovarian Cancer. Genes. Feb 2024. https://doi.org/10.3390/genes15020219 (barili2024geneticbasisof pages 2-4)
- Parsons MT et al. Evidence‑based recommendations for gene‑specific ACMG/AMP variant classification (ClinGen ENIGMA). medRxiv. Jan 2024. https://doi.org/10.1101/2024.01.22.24301588 (ismail2024brca1andits pages 11-13)
- Baradács I et al. PARP inhibitor era in ovarian cancer treatment: systematic review and meta‑analysis. J Ovarian Res. Feb 2024. https://doi.org/10.1186/s13048-024-01362-y (barili2024geneticbasisof pages 2-4)


References

1. (ismail2024brca1andits pages 1-2): Tala Ismail, Safa Alzneika, Emna Riguene, Salwa Al-maraghi, Aya Alabdulrazzak, Noof Al-Khal, Sara Fetais, Angelos Thanassoulas, Halema AlFarsi, and Michail Nomikos. Brca1 and its vulnerable c-terminal brct domain: structure, function, genetic mutations and links to diagnosis and treatment of breast and ovarian cancer. Pharmaceuticals, 17:333, Mar 2024. URL: https://doi.org/10.3390/ph17030333, doi:10.3390/ph17030333. This article has 21 citations and is from a poor quality or predatory journal.

2. (barili2024geneticbasisof pages 2-4): Valeria Barili, Enrico Ambrosini, Beatrice Bortesi, Roberta Minari, Erika De Sensi, Ilenia Rita Cannizzaro, Antonietta Taiani, Maria Michiara, Angelica Sikokis, Daniela Boggiani, Chiara Tommasi, Olga Serra, Francesco Bonatti, Alessia Adorni, Anita Luberto, Patrizia Caggiati, Davide Martorana, Vera Uliana, Antonio Percesepe, Antonino Musolino, and Benedetta Pellegrino. Genetic basis of breast and ovarian cancer: approaches and lessons learnt from three decades of inherited predisposition testing. Genes, 15:219, Feb 2024. URL: https://doi.org/10.3390/genes15020219, doi:10.3390/genes15020219. This article has 42 citations and is from a poor quality or predatory journal.

3. (moser2025thirtyyearsof pages 1-3): Sarah C. Moser and Jos Jonkers. Thirty years of brca1: mechanistic insights and their impact on mutation carriers. Cancer discovery, 15 3:461-480, Mar 2025. URL: https://doi.org/10.1158/2159-8290.cd-24-1326, doi:10.1158/2159-8290.cd-24-1326. This article has 5 citations and is from a highest quality peer-reviewed journal.

4. (ismail2024brca1andits pages 7-9): Tala Ismail, Safa Alzneika, Emna Riguene, Salwa Al-maraghi, Aya Alabdulrazzak, Noof Al-Khal, Sara Fetais, Angelos Thanassoulas, Halema AlFarsi, and Michail Nomikos. Brca1 and its vulnerable c-terminal brct domain: structure, function, genetic mutations and links to diagnosis and treatment of breast and ovarian cancer. Pharmaceuticals, 17:333, Mar 2024. URL: https://doi.org/10.3390/ph17030333, doi:10.3390/ph17030333. This article has 21 citations and is from a poor quality or predatory journal.

5. (sherker2021tworedundantubiquitin‐dependent pages 12-13): Alana Sherker, Natasha Chaudhary, Salomé Adam, Anne Margriet Heijink, Sylvie M Noordermeer, Amélie Fradet‐Turcotte, and Daniel Durocher. Two redundant ubiquitin‐dependent pathways of brca1 localization to dna damage sites. EMBO reports, Nov 2021. URL: https://doi.org/10.15252/embr.202153679, doi:10.15252/embr.202153679. This article has 25 citations and is from a highest quality peer-reviewed journal.

6. (ismail2024brca1andits pages 11-13): Tala Ismail, Safa Alzneika, Emna Riguene, Salwa Al-maraghi, Aya Alabdulrazzak, Noof Al-Khal, Sara Fetais, Angelos Thanassoulas, Halema AlFarsi, and Michail Nomikos. Brca1 and its vulnerable c-terminal brct domain: structure, function, genetic mutations and links to diagnosis and treatment of breast and ovarian cancer. Pharmaceuticals, 17:333, Mar 2024. URL: https://doi.org/10.3390/ph17030333, doi:10.3390/ph17030333. This article has 21 citations and is from a poor quality or predatory journal.

7. (gracia2024proteinfoldingchaperonespredict pages 23-24): Brant Gracia, Patricia Montes, Angelica Maria Gutierrez, Banu Arun, and Georgios Ioannis Karras. Protein-folding chaperones predict structure-function relationships and cancer risk in brca1 mutation carriers. Cell reports, 43:113803-113803, Feb 2024. URL: https://doi.org/10.1016/j.celrep.2024.113803, doi:10.1016/j.celrep.2024.113803. This article has 9 citations and is from a highest quality peer-reviewed journal.

## Citations

1. gracia2024proteinfoldingchaperonespredict pages 23-24
2. moser2025thirtyyearsof pages 1-3
3. barili2024geneticbasisof pages 2-4
4. https://doi.org/10.3390/ph17030333,
5. https://doi.org/10.1016/j.celrep.2024.113803,
6. https://doi.org/10.15252/embr.202153679,
7. https://doi.org/10.1038/s41586-024-07909-9,
8. https://doi.org/10.1038/s41586-024-07910-2,
9. https://doi.org/10.1038/s41586-024-07909-9;
10. https://doi.org/10.1038/s41586-024-07910-2
11. https://doi.org/10.3390/ph17030333
12. https://doi.org/10.1016/j.celrep.2024.113803
13. https://doi.org/10.1186/s13048-024-01362-y
14. https://doi.org/10.3390/genes15020219
15. https://doi.org/10.1101/2024.01.22.24301588
16. https://doi.org/10.15252/embr.202153679
17. https://doi.org/10.1038/s41586-024-07909-9
18. https://doi.org/10.3390/genes15020219,
19. https://doi.org/10.1158/2159-8290.cd-24-1326,